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ABSTRACT  
Despite much effort investigating the etiology of Parkinson’s disease (PD), the causes and the 
exact mechanisms underlying the disease remain elusive. Braak’s hypothesis suggests that 
PD pathology may start in the enteric nervous system and later spread to the brain via the 
vagus nerve. This hypothesis is further extended to the dual-hit hypothesis suggesting that 
environmental neurotropic pathogens may contribute to PD development through nasal and 
gut gateways that are in direct connection with each other via inhalation and ingestion. 
Mounting evidence also suggests the importance of neuroinflammation in the pathogenesis of 
PD. In this thesis, I aimed to explore the etiology of PD focusing on developmental origins 
related to early infection and inflammation, gastrointestinal aspects, and olfactory function 
using various register and population based datasets. 
In Study I, we conducted a cohort study to examine developmental aspects of PD regarding 
early life infection, parental age at birth, multiple birth. We considered birth order, sibship 
size, birth seasonality, and flu activity in the year of birth as surrogates for early infection and 
inflammation. Overall, we found that early life characteristics were not associated with future 
risk of PD, indicating little support for the importance of early life aspects in PD etiology. 
In Study II, we evaluated vagotomy and its subtypes (truncal and selective vagotomies) in 
relation to PD risk in a matched cohort. We found that truncal vagotomy, with the nerve trunk 
fully resected, appeared to be associated with a decreased risk of PD more than five years 
after the surgery, while selective vagotomy was not associated with the risk of PD. The 
results provide preliminary evidence supporting Braak’s hypothesis. 
In Study III, we conducted a nested case-control study in the Swedish total population and 
a cohort study in Swedish twins to investigate irritable bowel syndrome (IBS) diagnosis as 
well as IBS based on self-reported symptoms in relation to the risk of PD. The results 
demonstrated that IBS was linked to an elevated risk of PD. The findings add additional 
evidence suggesting the importance of gut-brain-axis in PD development. 
In Study IV, we examined whether poor olfaction is associated with long-term mortality and 
potential explanations for such association among older adults in a community-based cohort. 
We found that poor olfaction was associated with higher long-term mortality and that part of 
the association was explained by neurodegenerative diseases, in particular, PD and dementia, 
and body weight loss. 
  
In summary, by taking advantage of Swedish nationwide registers, we provide some 
evidence supporting Braak’s hypothesis and the importance of the gut-to-brain axis in PD 
development. Our data, however, do not support the importance of developmental origins 
of PD. Additionally, we confirmed the association between poor olfaction and mortality in 
healthy older adults from the Health, Aging and Body Composition study and identified PD 
or dementia and body weight loss as part of the potential mechanisms underlying the 
association. 
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1 BACKGROUND  
Two hundred years ago, London doctor James Parkinson first described “paralysis agitans” in 
his work “An Essay on the shaking Palsy” (1871) 1. The disease was later renamed as 
Parkinson’s disease (PD). PD is the second most common aging-related neurodegenerative 
disorder after Alzheimer’s disease. Due to selective loss of dopaminergic neurons in the 
substantia nigra pars compacta, PD is characterized by cardinal motor symptoms of tremor, 
bradykinesia, rigidity, and postural instability 2. PD also has a long prodromal phase, with 
non-motor symptoms of constipation, olfactory loss, psychiatric symptoms, and rapid eye 
movement sleep behavior disorders occurring up to several decades before the onset of motor 
symptoms 3, 4. Despite a 200-year effort to understand PD etiology, the exact causes and 
underlying mechanisms of the disease remain unclear. Genetic factors only account for 5-
10% of cases 5, while the majority of PD cases are sporadic – indicating the importance of 
environmental components in PD etiology. Historically, research on PD etiology has focused 
on the brain and the period of late adulthood. In the past 15 years, new insights have emerged 
regarding the concept that PD pathology may originate in peripheral organs during the long 
prodromal phase and spread to the brain via nasal and gut routes 6, 7. In this thesis, different 
epidemiological approaches were used to explore the etiology of PD beyond the brain and 
late adulthood, with special focus on early life infection or inflammation, gastrointestinal (GI) 
aspects, and olfaction. 
1.1 PARKINSON’S DISEASE (PD) CLINICAL FEATURES 
1.1.1 Motor symptoms 
Motor manifestations of PD only present after about 60% of dopaminergic neurons have died 
2. Cardinal motor symptoms include 1) tremor (both rest and action tremor), 2) rigidity, 3) 
bradykinesia (i.e. slowness of voluntary movements), and 4) postural instability (often occurs 
late in the disease) 8. Moreover, asymmetry of motor onset is common in most PD patients 8.   
1.1.2 Non-motor symptoms 
Non-motor symptoms may occur in both clinical and preclinical stages (i.e. prior to the motor 
onset) of PD 3, 4. A meta-analysis demonstrates that prevalence of hyposmia is 75.5%, 
constipation 50%, anxiety 39.9%, rapid eye movement sleep behavior disorders (RBD) 37%, 
depression 36.6%, and daytime sleepiness 33.9% in PD patients 3, 4. Strong evidence suggests 
that constipation, olfactory deficit, RBD, and depression can occur many years before PD 
diagnosis 3, 4, 9. Non-motor symptoms that arise in the preclinical stage of PD are commonly 
referred to as prodromal non-motor or premotor symptoms. Selected PD premotor symptoms 
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and the corresponding time periods preceding PD diagnosis have been summarized for 
constipation (up to 20 years), depression (within 5 years), hyposmia (within 4 years), RBD 
(up to 10-29 years), anxiety (could be > 20 years), and daytime sleepiness (up to 10 years) 9. 
Moreover, lower heart rate variability has also been recently linked to an increased PD risk 
indicating cardiac dysautonomia in the prodromal stage of PD10.  
1.1.3 Clinical diagnosis criteria 
At present, reliable biomarkers and specific neuroimaging techniques are not yet available for 
the clinical diagnosis of PD. Instead, PD diagnosis is generally made upon cardinal motor 
symptoms and signs, duration of the symptoms, exclusion of alternative diagnoses, and 
response to antiparkinsonian drugs. Several sets of clinical diagnostic criteria for PD have 
been proposed: the UK Parkinson’s Disease Society Brain Bank criteria include postural 
instability not caused by other differential diagnosis11, while Gelb et al. emphasize the 
asymmetric onset and exclusion of postural impairment 8. In 2015, the International 
Parkinson and Movement Disorder Society (MDS) developed clinical diagnostic criteria for 
PD (MDS-PD criteria) based on elements from the UK Brain Bank Criteria and omitting 
features that are no longer justified 12. With increasing recognition of non-motor symptoms in 
PD, the MDS-PD criteria also began to incorporate non-motor manifestations. It is worth to 
note that PD diagnoses given by experienced clinicians have been proven to be more accurate 
than those based on clinical criteria13. The goal of the MDS-PD criteria is to facilitate less 
experienced physicians to assign PD diagnoses as well as utilization in medical research 12.  
In general, the MDS-PD criteria classify PD into two certainty levels (i.e. clinically 
established PD and probable PD) in two steps: first, to define a parkinsonism, and second, to 
evaluate whether the parkinsonism is attributed to PD according to supportive, exclusion, and 
red flag criteria12. For illustration, the MDS-PD criteria are summarized below and detailed 
information on supportive, exclusion, and red flag criteria have been presented previously 12. 
Step 1: Define parkinsonism according to bradykinesia, in combination with at least either 
rest tremor or rigidity 
Step 2: Define PD diagnosis into certainty levels based on supportive, exclusion, and red flag 
criteria. 
Clinically Established PD: absence of absolute exclusion criteria; at least two supportive 
criteria; no red flags 
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Clinically Probable PD: absence of absolute exclusion criteria; presence of red flags 
counterbalanced by supportive criteria (i.e. one red flag must be compensated by least one 
supportive criterion and no more than two red flags are allowed)  
1.2 PATHOGENESIS AND PATHOLOGICAL HYPOTHESES 
The pathological marks of PD are essentially the selective neurodegeneration of 
dopaminergic neurons in the substantia nigra pars compacta (SNpc) and α-synuclein 
enriched Lewy bodies and Lewy neurites14. A variety of biological processes including 
increased oxidative stress, mitochondrial dysfunction, impairments in the ubiquitin-
proteasome system, and neuroinflammation can also contribute to PD pathogenesis 14-16. 
Normal α-synuclein is a soluble small protein mostly located in axons and their presynaptic 
terminals, and usually binds to membranes of synaptic vesicles 17. Under certain conditions, 
α-synuclein loses membrane-attachment and begins to self-aggregate together with some 
additional proteins, forming spherical and thread-like Lewy bodies or Lewy neurites 17.  
1.2.1 Braak’s staging system and Braak’s hypothesis (dual-hit hypothesis) 
Braak and colleagues proposed a staging system that explains the process of pathological 
development in some PD patients based on autopsy 17, 18. The staging system suggests that the 
Lewy pathology may originate in the peripheral enteric nervous system (ENS) and the 
olfactory bulb, and later spreads to the central nervous system (CNS) following six stages 17, 
18:  
Stage 1: lesions in ENS, the dorsal motor nucleus and/or adjoining reticular zone, 
olfactory bulb and related portions of anterior olfactory nucleus (medulla oblongata and 
olfactory system) 
Stage 2: lesions in caudal raphe nuclei, gigantocellular reticular nucleus, and coeruleus-
subcoeruleus complex (medulla oblongata and pontine tegmentum)  
Stage 3: lesions in substantia nigra pars compacta (midbrain) 
Stage 4: lesions in anteromedial temporal mesocortex (basal prosencephalon and 
mesocortex)  
Stage 5: lesions in high order sensory association areas of the neocortex and prefrontal 
neocortex (neocortex) 
Stage 6: lesions in first order sensory association areas of the neocortex, premotor area, 
and primary sensory area and motor field (neocortex) 
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Based on the staging system, Braak and colleagues hypothesized that an unknown pathology 
may originate in the gut and later enter the ENS and migrate to the CNS via the vagus nerve 
19. Braak’s hypothesis was further extended to the dual-hit hypothesis stating that neurotropic 
pathogens may enter the brain via two gateways: the nose and gut, which are in close contact 
with the outer environment and in direct connection with each other via inhalation and 
ingestion6, 7; and PD pathology may spread from the olfactory bulb to other parts of the brain 
and/or from the gut to the brain via the vagus nerve 6, 7. In line with stage I lesions, 
epidemiological studies consistently reported that constipation 20, 21 and olfactory dysfunction 
22, 23 are common prodromal symptoms occurring prior to PD motor onset 4. Pathological 
aggregation of α-synuclein was also found in different GI sites up 20 years before the PD 
diagnosis 24. Furthermore, the spread of α-synuclein was also supported by the finding in 
mice that aggregated α-synuclein was transferred from the olfactory bulb to other 
interconnected parts of brain 25. Moreover, coeruleus and subcoeruleus complex that are 
affected in stage II have been suggested to be involved in mood and sleep regulation, 
therefore in line with the presence of depression and RBD in the prodromal stage of PD 26.  
Criticisms have also been raised, partly because not all PD cases follow the system. However, 
there is an increasing body of evidence supporting Braak’s hypothesis in, at least, some PD 
patients 27. Another key point of the hypothesis is that PD-pathology migrates from the gut to 
the brain via the vagus nerve 7, 19. We attempted to explore the association between 
vagotomy, a surgical division of the vagus nerve, and risk of PD in Study II. And in Study 
IV, we examined olfactory dysfunction in relation to mortality and evaluated whether this 
association can be explained by neurodegenerative diseases including PD.  
1.2.2 Gut-brain-microbiota axis 
The gut-brain axis involves bidirectional neural communication between the ENS and CNS 
through the vagal nerve 28. Microbiota regulate the gut-brain axis through immunological, 
neuroendocrine, and direct neural mechanisms 29. For instance, lipopolysaccharide 
synthesized by pathogenic bacteria can induce innate immune system activation; gut bacteria 
can synthesize human neurotransmitters (e.g. γ-aminobutyric acid, serotonin, and dopamine) 
and stimulate afferent neurons in the ENS to send signals to the CNS through the vagus nerve 
30.  
The role of microbiota in modulating gut-to-brain interactions has been investigated in the 
etiology of PD 29. There is an increasing recognition of gut microbiota disturbances in PD 
patients 31-33. Although, the causal relationship between microbial alterations and PD remains 
unclear, it has been hypothesized that chronic inflammation induced by gut microbiota and 
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increased intestinal permeability may lead to systemic and neuro-inflammation, which in turn 
promote neurodegeneration in PD 30 34. The proposed involvement of the gut-brain-
microbiota axis in PD etiology is in line with early GI dysfunction such as constipation. 
Interestingly, dysfunction of the axis has also been linked to GI diseases, such as 
inflammatory bowel disease (IBD)35 and irritable bowel syndrome (IBS) 36. It is possible that 
certain pathological changes in the gut-brain-microbiota axis may underlie both GI diseases 
and PD. In Study III, we explored the association between IBS and subsequent PD risk. 
1.2.3 Neuroinflammation and neurodegeneration  
Mounting evidence suggests the important role of neuroinflammation in PD 
neurodegeneration 16. Dopaminergic neurons undergoing cell death can trigger inflammatory 
reactions such as microglia activation, astrogliosis, and lymphocyte recruitment, which 
contribute to a harmful inflammatory loop that drives neuron death further 16. Such a vicious 
circle may perpetuate neurodegeneration in PD 16. McGeer and colleagues first observed 
microglia activation in the substantia nigra of PD patients post-mortem 37. Clinical studies 
additionally found increased levels of circulating interleukin (IL)-1β, IL-2, IL-6, high 
sensitive C-reactive protein, and tumor necrosis factor α (TNF-α) in serum and cerebrospinal 
fluid of PD patients 38-41. Findings from animal models indicate that systemic 
lipopolysaccharide and TNF-α injection in mice can activate microglia and induce delayed 
and progressive loss of dopaminergic neurons 42. Moreover, mutations in PD-associated 
genes such as LRRK2 and HLA-DR have been related to immune functions 43. 
Epidemiological evidence has linked nonsteroidal anti-inflammatory drugs (NSAIDs) use, 
especially ibuprofen, to a 35-45% reduced PD risk 44. Although convergent evidence supports 
the involvement of inflammation in PD pathogenesis, the origin of the inflammatory process 
and its role in PD etiology remains unclear. In Study I, we attempted to explore the 
associations between factors related to early life inflammation or infection and the risk of PD 
in late adulthood. 
1.3 EPIDEMIOLOGY 
1.3.1 Incidence, prevalence, and mortality 
Incidence of PD varies from 1.5 to 22 per 100 000 person-years for all age groups 45 and 
estimates may differ by demographic characteristics of the study population, diagnostic 
criteria, and case-identification source 45. PD incidence is highly associated with age; disease 
onset before age 40 is very rare but incidence increases rapidly after the age of 60 45. PD 
incidence in men is about 50% higher than in women 45, 46. A meta-analysis has reported 
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pooled incidence (per 100 000 person-years) by age and sex based on 14 studies conducted in 
2001-2014 (Table 1.3.1) 46. Prevalence of PD also rises with age due to the increased 
incidence. Another meta-analysis including 47 studies summarized worldwide PD prevalence 
(per 100 000 persons) by sex and age group (Table 1.3.1) 47. Men have twice the prevalence 
of PD than women, but the difference become less prominent in older age groups 47.  
Mortality is approximately doubled in PD patients compared to the general population 45. 
Factors regarding disease severity, dementia, and age of onset can influence the mortality, 
and pneumonia is the most common cause of death in PD patients 45. Demented PD patients 
have higher mortality rates than non-demented PD patients, with the age- and sex-specific 
standardized mortality rate ratios being 3.10 and 1.15, respectively 48. Life expectancy 
decreases in nearly all age groups with PD, and particularly in patients with early age at 
onset. Life expectancy of PD patients vs. the general population was 38 vs. 49 years at age of 
onset 29-39, 21 vs. 31 years at age of onset 40-64, and 5 vs. 9 years at age of onset ≥65 49. 
Furthermore, adverse outcomes due to weight loss and malnutrition have been increasingly 
recognized in PD patients and linked to deleterious quality of life, disability, and mortality 50, 
51. 
 
Table 1.3.1 Incidence and prevalence of PD reported from two recent meta-analyses46 47  
 
1.3.2 Genetic and selected non-genetic factors in PD etiology 
Genetic components of PD have been estimated using linkage analysis, genome-wide 
association studies (GWAS), and family-based studies. Although cross-sectional twin studies 
suggested no heritability for PD 52, 53, a Swedish twin study using longitudinal information 
has estimated PD heritability at 34% 54.  Having a first degree relative or any relative with PD 
has been associated with higher PD risk 55, indicating influence of both genetics and shared 
environment. Six monogenic forms of PD have been identified with alpha synuclein, Parkin, 
PINK1, and DJ-1 being related to early-onset PD, and LRRK2 and VPS35 being related to 
late-onset PD 5. GWAS have identified 26 genomic loci related to late-onset sporadic PD 56. 
However, evidence jointly suggests that genetics only explain 5-10% of PD cases 5, 
prompting the importance of environmental influence in PD etiology. 
Age group Pooled incidence (per 100, 000 
person years) 
 Pooled prevalence (per 100, 000 
persons) 
 Men Women  Men Women 
40-49 3.57 3.26  36 45 
50-59 14.67 8.43  134 41 
60-69 58.22 30.32  389 392 
70-79 168.58 93.32  932 813 
80+ 258.47 103.45  2101 1517 
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Strong evidence suggests a lower PD risk for smoking and caffeine intake and higher PD risk 
for exposure to pesticide. A large meta-analysis has estimated relative risk of PD comparing 
ever- versus never-smokers at 0.64 (95% CI=0.60-0.69) 55. Similarly, a lower relative risk of 
PD for caffeine intake has been estimated at 0.67 (95% CI=0.58-0.76) 55. History of pesticide 
use has been linked to a higher relative risk of PD equal to 1.78 (95% CI=1.50-2.10) 55. 
Several other non-genetic factors have also been studied but evidence is limited and 
inconclusive (Table 1.3.2). 
 
Table 1.3.2 Summary of selected non-genetic factors related to PD risk  
Positive association Inverse association 
 Pesticides55  
 Farming/agriculture55 
 Rural living 55 
 Head injury57, 58  
 Anti-hypertensive drugs55, 59 
 Well water 55 
 Rosacea 60 
 Smoking55 
 Caffeine55 
 Alcohol 55, 61 
 Physical activity 62 
 NSAIDs 55, 63 
 Hypertension 55 
1.4 NON-GENETIC FACTORS IN PD ETIOLOGY STUDIED IN THE THESIS 
1.4.1 Sibling structure, birth season and month, influenza activity in the year 
of birth, and parental age 
According to the developmental origin of disease hypothesis, environmental exposures such 
as infection occurring during pre- and neo-natal periods may alter brain development and in 
turn affect the susceptibility to neurodegenerative diseases64, 65. Evidence supporting this 
hypothesis has been reported for the association of birth order, sibship size with Alzheimer’s 
disease (AD) 66, amyotrophic lateral sclerosis 67 and schizophrenia 68. It is likely that birth 
order and sibship size are merely surrogates for childhood common infections within the 
household. The developmental origin could be equally important for PD etiology and yet has 
been rarely tested in epidemiological studies. Early-life inflammatory triggers, such as 
infections, may result in continuing changes of cytokine production, number and function of 
microglial cells 69. Animal models have shown that mice exposed to lipopolysaccharide in 
utero were born with fewer dopamine producing neurons 70. Two epidemiological studies 
reported no association between birth order, sibship size, and PD risk 71, 72, but results had 
large statistical uncertainty. Although controversial73-75, season and year of birth, as indicators 
of intrauterine infection, revealed a peak of PD in births between March to June and births 
clustering in influenza pandemic years 76, while another study reported a moderate but non-
significant increased PD risk among those born in summer versus spring seasons 72. 
Moreover, older parental age at birth might relate to future disease susceptibilities due to the 
higher mutation rate and oxidative stress in germ cells 77, 78. Taken together, the potential role 
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of early life factors and a related developmental origin of PD has not been adequately 
investigated. 
1.4.2 Vagotomy  
One important aspect of Braak’s hypothesis is that PD pathology may spread from the gut to 
the brain via the vagus nerve. Supporting evidence has been reported from animal models: in 
mice, intragastrical rotenone administration induced α-synuclein accumulation in the ENS 
and subsequent PD-like pathology in the vagal dorsal motor nuclei, spinal cord, and SNpc79, 
while resection of the vagal nerves before rotenone treatment delayed the spread of PD-like 
pathology 80. Vagotomy was the gold standard surgical treatment for peptic ulcer to decrease 
gastric acid secretion before the recognition of Helicobacter pylori 81. Nowadays, the 
indication for vagotomy has been shifted to complications due to peptic ulcer 81. There are 
three types of vagotomy: truncal, selective, and highly selective (Fig 1.4.2) 81. In truncal 
vagotomy, resection of nerve trunks is performed above the celiac and hepatic branches, 
while selective vagotomy spares the celiac and hepatic braches and highly selective 
vagotomy only eradicates innervation to the acid and pepsin-producing cells 81. According to 
Braak’s hypothesis, if aggregated α-synuclein migrates from the gut to the brain via the vagus 
nerve, it is conceivable that truncal vagotomy may reduce PD risk, while selective and highly 
selective vagotomy may have a smaller or null effect. A Danish register-based study reported 
a lower risk for PD among individuals with truncal vagotomy more than 20 years after the 
surgery 82. The results however could not be replicated in a re-analysis of the same study 
population 83. Hence, further investigation on vagotomy and PD risk is warranted. 
Fig 1.4.2. Illustration of normal 
vagal anatomy and types of 
vagotomy (Reprinted from 
Glasgow and Mulvihill, with 
permission from Wiley) 81 
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1.4.3 Irritable bowel syndrome (IBS) 
IBS is a common disorder characterized by a group of symptoms consisting of recurrent 
abdominal pain, discomfort, and alterations of bowel habits 36, 84. According to prevailing 
stool patterns, IBS is classified into three subtypes: IBS-diarrhea, IBS-constipation, and IBS-
mixed with both symptoms or neither85.  Mechanisms related to IBS development involve 
genetic factors, post-infectious changes in the gut, brain-gut interaction, activation of the 
immune system, alterations in the gut microbiome, increased intestinal permeability, altered 
gut motility, visceral sensation, or bile salt metabolism 36, 84. IBS and PD may have certain 
shared symptoms and etiology including constipation, dysregulation of gut-brain axis, 
disturbance of gut microbiota and related intestinal inflammation, and increased intestinal 
permeability 34, 36. Evidence on IBS and subsequent PD risk is sparse. A cohort study based 
on data from the Taiwan National Health Insurance program reported a 48% higher risk of 
PD for IBS patients compared to individuals without IBS 86. Several limitations may exist in 
this study, including a limited follow-up period, a possible under-diagnosis of IBS, potential 
confounding by life style factors (e.g. smoking and alcohol consumption), and surveillance 
bias.  
1.4.4 Olfaction  
Olfaction impairment is common in older adults; the prevalence was estimated at 20-30% 
among people over 50 years and 60% among those over 80 years87-89. Poor sense of smell has 
a deleterious impact on safety 90, nutrition 91, and quality of life 92. Converging lines of 
evidence also suggest that impaired olfaction in particular predicts PD, AD, dementia, and 
cognitive decline9, 93, 94. Several studies have linked olfactory dysfunction to higher mortality 
95-100, however these studies have mainly focused on all-cause mortality and had a limited 
follow-up period. Further, little is known about mechanisms underlying the association 
between olfaction and higher mortality among older adults. Although neurodegenerative 
diseases 95-98, 100, poor nutrition 96-98, food or gas poisoning 97, 98, fire or hazardous 
environment 101 have been hypothesized to affect mortality in individuals with olfactory 
dysfunction, little empirical data on this research area exists.  
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2 AIMS  
In this thesis, we aim to first, explore PD etiology based on Braak’s hypothesis, gut-to-brain-
microbiota axis, and neuroinflammatory mechanisms; and second, examine whether poor 
olfaction is related to mortality and explore the potential explanations including 
neurodegeneration due to PD. 
Specific objectives include: 
I. To study sibling structure, birth season and month, influenza activities in the year of birth, 
as proxies for early infection and inflammation, and parental age in relation to PD risk  
II. To examine the association between vagotomy and risk of PD 
III. To examine the association between IBS and risk of PD 
IV. To examine olfactory impairment is associated with long term all-cause and cause-
specific mortalities; second, what are the potential explanations for the association between 
olfactory function and death. 
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3 DATA SOURCES AND MEASUREMENTS  
3.1 SWEDISH NATIONAL HEALTH AND POPULATION REGISTERS (STUDIES I-
III) 
Studies I-III were conducted based on linkage of multiple Swedish national health and 
population registers via the unique personal identity number available for all residents in 
Sweden.  
The Swedish Total Population Register (TPR) was established in 1968 and is maintained by 
Statistics Sweden. It contains information on, for instance, birth, death, marital status, family 
relationships, and dates of immigration (from 1969) and emigration (from 1961) 102.  
The Swedish Multi-Generation Register (MGR) is a part of the TPR and holds information on 
biological and adoptive parents for individuals (index persons) who were born in 1932 or 
later and lived in Sweden in 1961102, 103. The MGR has 97% coverage of all mothers and 95% 
coverage of all fathers for Swedish born index persons 103. The corresponding coverage for 
foreign-born residents is 27% and 22%, respectively 103. The register provides a unique 
resource to study the influence of family structure on diseases and conditions 103. In Study I, 
we retrieved information on sibling structure and parental age from the MGR. 
The Swedish Population and Housing Censuses were conducted by Statistics Sweden every 
five years from 1960 to 1990 to collect information on housing, civil status, educational 
attainment, income, occupation, and social class 104. Studies II and III were based on the 
censuses targeting the entire Swedish population in 1970 and 1980, respectively. 
The Swedish Twin Registry (STR) was established in the late 1950s. It is a nationwide 
population-based register including more than 194,000 twins who were born between 1886 
and 2008 105, 106. Data collection has been done through several waves of questionnaires 105, 106 
and linkage to different national health and population registers 105, 106. In the Screening 
Across the Lifespan of Twins Study (SALT), telephone interviews were carried out in 1998-
2002 with twins born before 1958 105, 106 to collect information on a broad spectrum of 
diseases and conditions, medication use, life style factors (e.g. smoking, alcohol 
consumption, and diet), occupation, and education 105, 106. In Study III, we obtained 
information on abdominal symptoms related to IBS and other covariates from SALT. 
The Swedish National Patient Register (NPR) was established in 1964 to collect information 
on medical diagnoses and dates of admission and discharge of hospitalization. Data collection 
started in six counties of Sweden and the NPR became nationwide in 1987 107. Psychiatric 
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care was included in 1973107. Surgical day-care procedures were included in 1997 and >80% 
outpatient specialist care is covered since 2001. Although private caregivers are not included, 
the NPR covers nearly 100% of outpatient records from public caregivers 107. Primary care is 
currently not included in the NPR107. We identified PD diagnoses (Studies I-III), vagotomy 
(Study II), IBS diagnoses (Study III), and comorbidities (Study II and III) from the NPR. 
The Cause of Death Register (CDR) was established to collect nationwide information on 
deaths since 1952 and became digitalized in 1961108. Coverage is virtually complete for all 
deaths since 1952 and records information on date of death, underlying and contributing 
causes of death, place of death, and death abroad 108.  
3.2 THE HEALTH, AGING, AND BODY COMPOSITION STUDY (STUDY IV) 
The Health, Aging and Body Composition (Health ABC) study is an interdisciplinary study 
designed to investigate risk factors of health outcomes among healthier older adults109. The 
study recruited 3,075 well-functioning community-dwelling older adults (48.4% men and 
41.6% blacks) aged 70-79 years during 1997-1998 in Pittsburgh, Pennsylvania, and 
Memphis, Tennessee109. Eligibility criteria were 1) no difficulty to walk a quarter mile or 
climb ten steps, or to perform activities of daily living, 2) no history of life-threatening cancer 
in the past three years, and 3) no plan to move out of the area in the next three years 109. 
Participants in the Health ABC study were followed with annual clinical or home visits 
through year 6 and then in year 8, 10, 11, and 16 109. Semi-annually telephone interviews 
were performed to update health status between enrollment and year 15 and then quarterly 
through year 17109. Data collection and follow-up were completed in 2014 109. Study IV was 
based on data retrieved from the Health ABC Study. 
3.3 OUTCOME ASCERTAINMENT 
3.3.1 PD ascertainment (Studies I-III) 
PD risk is the primary outcome in Studies I, II, and III.  We identified PD cases from the 
NPR based on primary and secondary diagnoses at hospital discharge or outpatient visit using 
the Swedish revision of the International Classification of Diseases (ICD) codes (ICD-7: 350 
in 1964-1968; ICD-8: 342 in 1969-1986; ICD-9: 332.0 in 1987-1996; and ICD-10: G20 from 
1997 onward). Date of PD identification was defined as date of first hospital admission or 
outpatient contact. In Study IV, we examined PD as a potential mediator of the association 
between olfactory impairment and all-cause mortality. PD diagnoses were adjudicated by two 
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movement disorder specialists in agreement after comprehensive reviews of self-reported PD 
diagnoses, medication use, hospitalization surveillance, and cause of death 23.  
3.3.2 All-cause and cause-specific mortality (Study IV) 
In Study IV, we examined the association between olfaction and all-cause as well as cause-
specific mortality. Investigators from the Health ABC study closely recorded participants’ 
survival through comprehensive hospitalization records and death certificates. For each death, 
a knowledgeable proxy was interviewed to obtain detailed information on the death event and 
physical functioning of the study participant while alive. A team of medical experts reviewed 
information from interviews, hospitalization records, death certificates, and autopsy data and 
adjudicated the underlying cause of death by consensus. We examined all-cause mortality 
and underlying causes of death due to 1) dementia or PD; 2) cardiovascular diseases; 3) 
cancer; and 4) respiratory diseases. 
3.4 EXPOSURE AND OTHER VARIABLE ASCERTAINMENT 
3.4.1 Sibling structure, birth season and month, parental age, and influenza 
activity in the year of birth (Study I) 
In Study I, we retrieved information on sibling structure, parental age, season and month of 
birth from the MGR. For each participant, we identified full and maternal half siblings. 
Exposure variables were subsequently calculated  as follows: sibship size (1, 2, 3, or ≥4), 
number of older/younger siblings (0, 1, 2, or ≥3), birth interval between nearest older/younger 
siblings (<2, 2–6, or >6 years), parental age at birth (≤20, 21–25, 26–30, 31–35, 36–40, or 
>40 years), multiple births (yes/no), birth month, and birth season. We obtained historical 
information about influenza-like illness activities in 1932-1970s from the Swedish Public 
Health Agency. Since 1911, the Swedish Public Health Agency requested general 
practitioners in most parts of Sweden to report influenza-like illness every week or month. 
Annual burden of influenza-like illness was calculated by dividing the number of cases by the 
corresponding mid-year population size110 and subsequently categorized into low, 
intermediate, and high burden using the cut-offs of 500/100,000 and 1,500/100,000 person-
years. We considered variables regarding sibling structure, birth season and month, and flu 
activity in the year of birth as surrogates for early life infection and inflammation. 
3.4.2 Vagotomy (Study II) 
In Study II, We identified vagotomized patients from the NPR using codes from the Swedish 
Classification of Operations and Major Procedures: 4471-4478, 4411-4416, 4418-4419, 4451, 
and 4453 during the period 1964-1996, and JDG00, JDG01, JDG10, JDG11, JDG96 and 
 16 
JDG97 from 1997 onward. Following review of the surgical codes by an expert in 
gastroenterological surgery, we further categorized vagotomy into truncal and selective (i.e. 
including both selective and highly selective). The date of hospital discharge was defined as 
the date of the surgery.  
3.4.3 IBS (Study III) 
In Study III, we examined both register-based 
IBS diagnosis as well as self-reported symptoms 
based IBS in relation to PD risk. IBS diagnoses 
were identified from the NPR according to the 
Swedish revisions of ICD codes (ICD-7: 573.10, 
573.21, 573.22 in 1964–1968; ICD-8: 564.10, 
564.11, 564.19 in 1969–1986; ICD-9: 564B in 
1987–1996; and ICD-10: K58 from 1997 
onward). Patients with alternative diagnosis of 
inflammatory bowel disease, celiac disease, or 
colorectal cancer in the NPR were excluded.  
In SALT, we ascertained IBS patients using a 
previously reported algorithm based on self-
reported abdominal symptoms (Fig 3.4.3) 111. 
Similarly, patients with diagnoses of 
inflammatory bowel disease, celiac disease, or 
colorectal cancer based on the NPR were 
excluded. 
 
3.4.4 Olfaction (Study IV) 
In the Health ABC study, sense of smell was evaluated at the year 3 clinical examination in 
1999-2000 using the 12-item Brief Smell Identification Test (BSIT) 112. The BSIT is a simple 
and cost-effective test for smell identification and has been validated and widely used in 
clinical and epidemiological settings 112, 113. Participants scratched and smelled one of twelve 
odorants common in daily life, and then identified the odor from four alternatives written in a 
paper booklet 112. Each correct answer was scored as one point with a total score ranging 
from 0 to 12 112. We further categorized the total BSIT score into poor, moderate, and good 
Ever had recurrent abdominal discomfort 
Yes 
 Abdomen discomfort last at least 7 days 
per month  AND 
 Abdomen discomfort during the past year 
Yes 
 Pain in the lower abdomen OR 
 Pain in another part of the abdomen OR 
 Constipation OR 
 Diarrhea OR  
 Feel bloated OR  
 Feeling of incomplete defecation OR 
 Pain when feces becomes looser and 
defecation more frequently OR  
 Pain alleviated after defecation 
Yes 
 Inflammatory bowel disease OR 
 Celiac disease OR 
 Colorectal Cancer 
No 
Irritable bowel syndrome 
Fig 3.4.3 Definition of IBS in SALT Swedish twins 
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olfactory function using cut-offs of 8, 9-10, 11-12. The cut-offs correspond to the tertiles of 
BSIT distribution in the sample.  
3.4.5 Covariates 
In the statistical analyses, we adjusted for several covariates to control for confounding based 
on evidence from the literature and subject knowledge. We considered age and sex in Studies 
I-IV, family history of PD and parental socioeconomic status in Study I; educational 
attainment in Study III; country of birth, comorbidity, and chronic obstructive pulmonary 
disease (COPD) as a proxy for smoking in Studies II and III;  Osteoarthritis and 
rheumatologic disease as proxies for use of NSAIDs in Study II; smoking and alcohol 
consumption in Study III;  demographics (e.g., age, sex, race, and education), 
anthropometrics (e.g. weight and height), lifestyle factors (e.g., smoking, alcohol drinking, 
and physical activity), and self-reported health status (i.e., excellent, very good, good, fair, 
and poor), a list of baseline diseases, and selective biomarkers in Study IV.  
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4 METHODS 
4.1 TYPES OF STUDY DESIGN  
4.1.1 Standard cohort study (Studies I, III, IV) 
In a cohort study, the general goal is to compare incidence, rate, or time to an outcome among 
sub-cohorts that are made up of people who share a common condition, e.g. exposed and 
unexposed subgroups114. It is a longitudinal design, in which exposed and unexposed cohorts 
are prospectively followed for the occurrence of an outcome.  
In Study I, we identified more than 3.5 million individuals in the MGR, who were born 
between 1932 and 1970 in Sweden, alive, and had no previous diagnosis of PD on January 1, 
2002. The cohort was followed until PD diagnosis, death, emigration out of Sweden, or 
December 31, 2010, whichever occurred first. We compared PD risk among individuals with 
different sibling structure, birth month and season, and flu activity in the year of birth, and 
parental age. 
In Study III, we examined the association between IBS and subsequent PD risk using both 
register-based and self-reported symptoms based IBS cases. Self-reported IBS in relation to 
PD risk was explored in a cohort study based on all twins in the STR who responded to the 
SALT interview during 1998-2002 (N= 44,919). We excluded twins who discontinued 
participation, or emigrated, or had missing on linkage information or date of emigration 
(N=61), or had pre-existing PD according to self-report or a diagnosis from NPR (N=96), or 
had missing on self-reported IBS (N=529). In total, we followed 44,233 twins until date of 
PD diagnosis, death, emigration out of Sweden, or December 31, 2014, whichever occurred 
first.  
In study IV, we elucidated the association between olfactory impairment and all-cause as 
well as cause-specific mortality. We also investigated possible explanations to the 
associations. A total of 2,544 participants had their sense of smell measured at the year 3 
clinical examination in 1999-2000 (baseline) using the 12-item BSIT112. Seven participants 
with missing BSIT score were excluded leaving 2,537 participants who were followed from 
baseline until date of death, last alive contact, or September 30, 2014.  
4.1.2 Matched cohort study (Study II) 
In contrast to randomized trials, a causal effect that one aims to evaluate in observational 
studies is usually confounded by causes shared by the exposure and outcome115. Different 
methods are available to adjust for confounding, for example standardization, stratification, 
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A. 1:1 matched cohort design (follow-up 
indicated by the bolded lines) 
B. 1:1 nested case-cohort design 
regression modelling, etc. 115, 116. In the presence of strong confounding, strategies applied to 
study designs usually achieve higher efficiency compared to the statistical methods 
mentioned above 116. One common way is to match by confounders, for instance, age and sex 
116. An example of 1:1 matched cohort design is depicted in Fig 4.1A.  
In Study II, we conducted a matched cohort study to explore the relationship between 
vagotomy and PD risk. Among 10,006 vagotomized patients ascertained from the NPR in 
1970-2010, 9,430 were included for fulfilling inclusion criteria of being born before 1970, 
living in Sweden, and free-of-PD before vagotomy. For each vagotomized patient, we 
randomly selected 40 PD-free reference individuals (from the 1970 census) individually 
matched on sex and year of birth on the date of vagotomy (index date). To minimize potential 
bias due to incomplete coverage of the NPR, we further restricted reference individuals to 
live in the counties covered by the NPR in 1977 according to their residential information in 
the census. In total, 9,430 vagotomized patients and 377,200 reference individuals were 
included in the study and followed from the index date to the date of PD diagnosis, death, 
emigration out of Sweden, or December 31, 2010, whichever occurred first. 
Fig 4.1 Example of matched cohort and nested case-control design. 
 
 
 
 
 
 
 
4.1.3 Nested case-control study (Study III) 
In a nested case-control study, the matching approach can also be used as a means of 
accounting for confounding. In a defined cohort, at each time point of case occurrence, a 
specified number of controls are selected among individuals who have not developed a 
certain disease 117. Key features of the nested case-control design include matching on time; 
cases and controls matched on confounding factors (e.g. age and sex), a selected control may 
later become a case, and a control can serve several cases 117. The nested case-control design 
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is popular since the sampling allows efficient analysis using a subset of a large cohort with 
substantial savings in resources and time 118. An example of 1:1 nested case-control design is 
depicted in Fig 4.1B.  
In Study III, we examined the relationship between IBS diagnosis and PD risk in a nested 
case-control study based on the 1980 census. PD cases were ascertained from the NPR 
between 1987 and 2010. For each PD case, we randomly selected 30 controls who were alive 
and living in Sweden, and currently without PD diagnosis, individually matched to the PD 
case on sex and year of birth on the date of PD diagnosis (index date). In total, 56,564 PD 
cases and 1,696,920 controls were included and compared regarding history of IBS diagnosis. 
4.2 STATISTICAL METHODS 
4.2.1 Survival analysis 
4.2.1.1 Cox proportional hazard model 
An important feature of time-to-event data is censoring. In standard survival analysis, it is 
important to assume that the censoring is non-informative, meaning that at any time, 
individuals who are censored have the same survival probability as those who are still at risk 
and being followed 119. This assumption is however difficult to test 119. The Cox proportional 
hazard model is commonly applied to analyze time-to-event data 120. Researchers often 
compare the hazard of a certain disease between two groups using the Cox proportional 
hazard model to estimate the hazard ratios (HRs). The model does not require any 
assumptions regarding the shape of underlying hazards, but assume that the ratio of the 
hazard function to a baseline hazard is constant over time (e.g. hazards of exposed and non-
exposed groups are proportional over time) 121. It has been discussed that in the presence of 
time-varying effects (i.e. HRs changing over time), presenting period specific HRs may be 
problematic due to certain selection bias 122. Alternatively, standardized survival or 
cumulative failure curves controlling for confounders are suggested to overcome this problem 
122. For example, one can calculate and generate standardized survival curves based on the 
Cox models using the stdReg R package123. Cox proportional hazard models were used in 
Studies I-IV, and, we presented age and sex adjusted cumulative incidence in Study II and 
standardized survival curves in Studies III and IV.  
4.2.1.2 Handling cluster data 
Most statistical regressions assume that observations are independent. This assumption 
however does not hold in studies including siblings, twins, or other types of correlated data. 
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Several analytical methods are available to address this issue for different purposes. When 
performing between-cluster analyses, one can estimate the robust standard error. We 
estimated the robust standard error in Studies I and III to account for relatedness in a family 
or twin pair. On the other hand, conditional effect within clusters can be estimated in matched 
cohort and nested case-control studies. We used stratified Cox models in Study II to estimate 
HRs and conditional logistic regressions in Study III to estimate odds ratios (ORs) 
conditional on sex and birth year matching pairs.  
4.2.2 Mediation analysis  
Mediation analyses performed in Study IV 
assumes that the causal directed acyclic graph 
(DAG) in Figure 4.2.2 depicts the true causal 
relationships between the exposure, mediators, 
and outcomes. The exposure was olfactory 
function categorized into three groups: poor, 
moderate, and good. The two mediators are 
baseline prevalent and incident dementia 
and/or PD (yes/no) (M1) and on-average yearly 
body weight loss ≥ 2% (M2).  
A sequential approach described by Steen et 
al.124 was used to decompose the total effect of olfaction on all-cause mortality into a natural 
direct effect (i.e. AY), an indirect effect through M1 (i.e. combined paths of AM1Y 
and AM1M2Y), and an indirect effect only mediated by M2 (i.e. AM2Y). To 
estimate the direct and indirect effects, we used a weighting approach described by Lange et 
al.125 that is suitable for common survival outcomes. Of note, regarding the mediation 
analysis, we have assumed 126: 1) no unmeasured exposure-outcome confounders given X0; 
2) no unmeasured mediator-outcome confounders given W1 and W2; 3) no unmeasured 
exposure-mediator confounders given X1 and X2; 4) no mediator-outcome confounder W1 
and W2 affected by A.  
Figure 4.2.2. Causal DAG for the Mediation Model 
where A = Olfaction, M1 = Dementia and/or 
Parkinson’s disease, M2 = on-average yearly weight 
loss ≥ 2%, Y = all-cause mortality, (X0, X1, X2, W1, W2) 
are confounding factors collectively called C. 
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5 MAIN RESULTS  
5.1 EARLY LIFE CHARACTERISTICS AND RISK OF PD (STUDY I) 
In Study I, we identified 8,779 PD cases, of which 80% were primary diagnoses, during a 
follow-up time of 27.1 million person-years. The overall crude incidence rate (per 100,000 
years) was 32.4 (39.5 for men and 25.2 for women). Mean age (±SD) at PD diagnosis was 65.1 
(±7.6) years. Overall, we did not observed any association between sibling structure and PD 
risk, except for a slightly decreased PD risk linked to having older siblings (Table 5.1.1). 
Compared to first-born children, those with at least one older sibling had 7% lower PD risk 
(HR=0.93, 95% CI: 0.89, 0.98).  No association was observed between parental age at birth and 
the risk of PD (Table 5.1.2). We did not find any clear pattern of PD risk related to month and 
season of birth or flu activity in the year of birth (Table 5.1.3).  
 
Table 5.1.1 Sibling structure and PD risk 
1 Adjusting for attained age, sex, birth year category, parental socioeconomic status, and stratified by family PD history 
 
 
 HR (95% CI)1 Wald test (p-value) 
Sibship size      0.57 
1 1  
2 0.97 (0.91-1.04)  
3 0.96 (0.90-1.03)  
≥4 0.95 (0.89-1.02)  
Older siblings     0.01 
0 1  
1 0.92 (0.87-0.97)  
2 0.98 (0.90-1.06)  
≥3 0.91 (0.82-1.01)  
Birth interval from the nearest elder sibling (years) 0.02 
No elder siblings 1  
<2   0.91 (0.84-0.98)  
2-6 0.94 (0.89-1.00)  
>6  0.93 (0.84-1.04)  
Younger siblings                                          0.52 
0 1  
1 1.01 (0.96-1.07)  
2 1.02 (0.95-1.09)  
≥3 0.96 (0.90-1.03)  
Birth interval from the nearest younger sibling (years) 0.94 
No younger siblings 1  
<2  0.99 (0.92-1.06)  
2-6 1.00 (0.95-1.06)  
>6 1.02 (0.95-1.09)  
Multiple birth  - 
No  1  
Yes 0.98 (0.83-1.16)  
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Table 5.1.2 Parental age and PD risk 
 HR (95% CI)1 Wald test (p-value) 
Maternal age category (years) 0.55 
≤20 1.01 (0.93-1.11)  
21-25 1  
26-30  1.05 (0.99-1.11)  
31-35  1.04 (0.97-1.11)  
36-40 1.05 (0.97-1.14)  
>40 0.98 (0.85-1.13)  
Paternal age category (years) 0.82 
≤20 0.91 (0.76-1.09)  
21-25 1.02 (0.95-1.09)  
26-30 1  
31-35 1.03 (0.97-1.09)  
36-40 1.01 (0.95-1.09)  
>40 1.03 (0.95-1.11)  
1 Adjusted for attained age, sex, birth year category, parental socioeconomic status, and stratified by family PD history. 
 
 
 
Table 5.1.3 Birth month, season, and influenza-like illness incidence in the year of birth in relation to 
PD risk 
 HR (95% CI)1 Wald test (p-value) 
Birth month  0.17 
JAN 1.05 (0.94-1.18)  
FEB 1.10 (0.99-1.23)  
MAR 1.16 (1.04-1.29)  
APR 1.10 (0.99-1.22)  
MAY 1.02 (0.92-1.14)  
JUN 1.03 (0.92-1.15)  
JUL 1.13 (1.01-1.26)  
AUG 1.14 (1.02-1.27)  
SEP 1  
OCT 1.09 (0.97-1.22)  
NOV 1.05 (0.93-1.18)  
DEC 1.07 (0.96-1.20)  
Season  0.44 
Spring (MAR-MAY) 1.05 (0.98-1.12)  
Summer (JUN-AUG) 1.05 (0.98-1.12)  
Autumn (SEP-NOV) 1  
Winter (DEC-FEB) 1.03 (0.97-1.10)  
Influenza-like illness category 
(cases/100 000 person years) 
0.56 
Low (<=500) 1  
Intermediate (500-1500) 0.98 (0.93-1.03)  
High (>1500) 1.07 (0.87-1.32)  
1 Adjusted for attained age, sex, birth year category, parental socioeconomic status, and stratified by family PD history. 
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5.2 VAGOTOMY AND RISK OF PD (STUDY II) 
In Study II, we compared the risk of PD among 9,430 vagotomized patients (3,445 truncal, 
5,978 selective) and 377,200 age and sex matched reference individuals. Mean age (±SD) on 
the index date (date of vagotomy) was 54.3 (±15.2) years and mean age at PD diagnosis was 
75.6 (±8.4) years. We identified 4,930 incident PD cases during 7.3 million person-years of 
follow-up time. Crude incidence (per 100,000 person-years) of PD was 61.8 for vagotomized 
patients (80.4 for truncal, and 55.1 for selective) and 67.5 for reference individuals. Fig 5.2.1 
depicts cumulative incidence of PD comparing truncal and selective vagotomized patients to 
their matched non-vagotomized individuals. 
Figure 5.2.1 Cumulative incidence of PD comparing vagotomized to the matched non-vagotomized 
individuals 
 
 
 
 
 
 
 
 
We observed that vagotomy was not associated with PD risk during the entire follow-up 
(Figure 5.2.2, HR=0.96, 95% CI=0.78-1.17), although truncal vagotomized patients appeared 
to have a lower risk than references. When restricted to > 5 year of follow-up, we found a lower 
risk of PD in truncal vagotomized patients (HR=0.59, 95% CI=0.37-0.93). Similar results were 
observed >10 and > 20 years after truncal vagotomy, but the risk reduction did not reach the 
statistical significance. On the other hand, we did not observe any association between selective 
vagotomy and risk of PD.  
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Figure 5.2.2 Overall and temporal relationship between vagotomy and risk of PD* 
 
 
 
 
 
 
 
 
* Models conditional on sex and birth year matching pairs, adjusted for country of birth, chronic obstructive pulmonary, 
diabetes, vascular diseases, rheumatologic disease, osteoarthritis, and comorbidity index. 
5.3 IBS AND RISK OF PD (STUDY III)  
In Study III, we aimed to explore register-based IBS diagnosis and IBS based on self-
reported symptoms in relation to PD risk in two complementary data sources. In the nested 
case-control study based on the entire Swedish population, we included 56,564 PD cases 
diagnosed by hospital specialists and 1,691,978 sex and birth year matched controls. IBS was 
associated with a 43% higher risk of PD during the entire observational time (Table 5.3.1). 
We also observed a 50% increased PD risk ≥5 years and a 39% increased PD risk more than 
10 years after IBS diagnosis. The association appeared to be stronger among IBS patients 
diagnosed at older (≥ 50 years) than younger age (<50 years), but the difference was not 
statistically significant (p for interaction=0.11). Stratified analyses showed similar results by 
sex and age on the index date. Sensitivity analyses yielded attenuated associations when 
restricting to primary PD diagnosis, or when adjusting for number of hospital visits, or when 
adjusting for comorbidity with depressive disorders and anxiety (eTable 4 in Study III 
supplemental data). 
In the cohort study based on the STR, we followed 2,962 self-reported IBS patients and 
41,271 non-IBS persons. During an average of 13.7 years of follow-up, 440 persons 
developed PD (31 with IBS, 209 without IBS). A similar magnitude of risk increase in PD 
was noted for self-reported IBS (HR=1.39, 95% CI=0.95-2.03) after adjusting for attained 
age, sex, educational attainment, history of smoking, alcohol consumption in the last month, 
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and comorbidity index. Standardized survival curves (over the distribution of covariates) also 
showed higher PD risk in IBS patients compared to non-IBS individuals (Fig. 5.3.1).  
Table 5.3.1 Irritable bowel syndrome diagnosis and risk of PD, nationwide nested case-control analysis 
  
 PD cases N (%) Controls N (%) OR (95% CI)1 
Non IBS 56325 (99.6) 1691978 (99.7) 1 
IBS 239 (0.4) 4942 (0.3) 1.43 (1.26-1.63) 
Years before index date  
<5 91 (0.2) 2019 (0.1) 1.33 (1.08-1.65) 
≥5 148 (0.3) 2923 (0.2) 1.50 (1.27-1.77) 
≥10 82 (0.1) 1751 (0.1) 1.39 (1.11-1.74) 
Age at IBS diagnosis, years  
<50 26 (0.0) 725 (0.0) 1.07 (0.72-1.58) 
≥50 213 (0.4) 4217 (0.2) 1.49 (1.30-1.72) 
Stratified by Sex   
Male 85 (0.2) 1682 (0.1) 1.49 (1.20-1.86) 
Female 154 (0.3) 3260 (0.2) 1.40 (1.19-1.65) 
Stratified by age on the index date, years  
≤69 75 (0.1) 1475 (0.1) 1.52 (1.20-1.91) 
70-79 97 (0.2) 2065 (0.1) 1.39 (1.13-1.70) 
≥80 67 (0.1) 1402 (0.1) 1.42 (1.11-1.81) 
1. Conditional on birth year and sex matching pairs, country of birth, educational attainments, chronic obstructive pulmonary, 
comorbidity index 
 
Fig. 5.3.1 Standardized survival functions and confidence intervals for PD among IBS and non-IBS 
subjects in SALT Swedish twins 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
5.4 POOR OLFACTION AND LONG-TERM MORTALITY (STUDY IV) 
Study IV examined the association between olfaction, all-cause, and cause-specific mortalities 
among 2,537 older adults in the Heath ABC study. A total of 1,565 participants had died during 
a median of 12.0 years of follow-up. Participants with poor and moderate olfaction had 51% 
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Fig 5.4.1 Standardized 
survivals curves and 
confidence intervals of all-
cause mortality for different 
olfactory function groups 
and 17% higher all-cause mortality, respectively (Table 4.5.1). Fig 5.4.1 depicts standardized 
survival curves indicating higher all-cause mortality in older adults with poor and moderate 
sense of smell compared to those with good sense of smell. Regarding cause-specific 
mortalities, poor sense of smell was strongly linked deaths due to dementia or PD and 
moderately linked to death due to cardiovascular diseases (Table 5.4.1). Olfactory function, 
however, was not associated with cancer or respiratory disease mortality. Fig 5.4.2 shows the 
standardized survival of cause-specific mortalities for different olfactory function groups. 
Table 5.4.1 Olfaction, total mortality, and selected cause-specific mortality in the Health ABC study 
Mortality  Death(N) Rate1 HR (95% CI)2 
All-cause mortality   
Good 433 44.6 1 
Moderate 524 55.6 1.17 (1.02-1.33) 
Poor 608 77.4 1.51 (1.33-1.72) 
Cause-specific mortality  
Dementia or Parkinson’s disease  
Good 56 5.8 1 
Moderate 70 7.4 1.23 (0.86-1.77) 
Poor 138 17.6 3.24 (2.34-4.49) 
Cardiovascular diseases  
Good 168 17.3 1 
Moderate 202 21.4 1.17 (0.95-1.44) 
Poor 219 27.9 1.39 (1.12-1.72) 
Cancers      
Good 119 12.3 1 
Moderate 130 13.8 1.04 (0.80-1.34) 
Poor 129 16.4 1.09 (0.84-1.42) 
Respiratory diseases   
Good 24 2.5 1 
Moderate 37 3.9 1.47 (0.86-2.48) 
Poor 29 3.7 1.37 (0.77-2.42) 
1: Mortality rate per 1000 person-years; 2: for all-cause mortality, adjusted for age, sex, education, BMI, drinking, briskly 
walking, self-reported general health status, cardiovascular diseases, cancer, diabetes, hypertension, depressive symptoms, 
stratified by race, smoking, chronic kidney disease; for dementia or Parkinson’s disease mortality stratified by race, smoking, 
and depressive symptoms; for the rest of the cause-specific mortalities: stratified by race and smoking. 
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Fig 5.4.2 Standardized survivals curves of cause-specific mortalities for different olfactory function 
groups. 
 
 
 
 
 
 
 
 
 
 
 
In mediation analyses (Table 5.4.2), 26.4% of the increased all-cause mortality associated with 
poor olfaction was mediated by paths through dementia or PD (i.e. path through dementia/PD 
only and path through dementia/PD and subsequent weight loss), whereas the proportion 
decreased to 15.3% among those with moderate olfaction. The corresponding proportion 
mediated only through weight loss was 18.3% and 33.0% for poor and moderate olfactory 
function groups, respectively.  
 
Table 5.4.2 Mediation analyses between olfaction and all-cause mortality 
Effect1 Olfaction  
Poor vs. Good 
HR (95% CI) 
% 
Mediated  
Olfaction 
Moderate vs. 
Good 
HR (95% CI) 
% 
Mediated 
Effect not through any mediator 1.32 (1.15-1.54) - 1.12 (0.99-1.28) - 
Indirect effect through dementia/PD 
 1.09 (1.05-1.12) 26.4% 1.02 (1.00-1.04) 15.3% 
Indirect effect only through mean yearly body weight loss ≥2% 
 1.05 (1.03-1.09) 18.3% 1.05 (1.02-1.08) 33.0% 
1: Adjusted for age, sex, education, BMI, drinking, briskly walking, self-reported general health status, cardiovascular diseases, 
cancer, diabetes, hypertension, depressive symptoms, stratified by race, smoking, chronic kidney disease 
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6 GENERAL DISCUSSION AND CONCLUSION  
6.1 RESULTS AND IMPLICATIONS 
In Studies I-IV, we investigated factors related to PD etiology beyond the brain and late 
adulthood, including early life characteristics, vagotomy, IBS, and olfaction. In Study I, we 
demonstrated that early life characteristics of sibling structure, parental age at birth, month and 
season of birth, or influenza burden in the year of birth had little influence on the risk for PD 
late in life. These results are generally in line with previous findings 71-75.   
In Study II, beyond the 5 year period post-surgery, truncal, but not selective, vagotomy 
appeared to be associated with a lower risk of PD compared to non-vagotomy individuals. A 
potential explanation may be that the spread of α-synuclein via the vagus nerve was reduced 
further after truncal versus selective vagotomy, because the truncal vagotomy targets 
anatomically much broader than the selective vagotomy. Our results are consistent with 
Svensson et al.’s paper that reported lower PD risk 20 years after the truncal vagotomy using 
the Danish registers 82. In line with these findings, phosphorylated a-synuclein was detected in 
the gut of prodromal PD patients on average seven years (ranging from four months to twenty 
years) prior to PD diagnosis 24. Additional investigations are needed to replicate the results and 
to further explore the potential temporal-spatial pattern in the spreading of α-synuclein. In 
contrast, Tysnes et al. did not replicate the reported lower PD risk after truncal vagotomy in the 
same Danish population 127. Discrepancy in the Danish data may partly be attributed to 
difference in methodology as well as large statistical uncertainty. Although preliminary, 
evidence from two independent studies supports Braak’s hypothesis that PD pathology may 
migrate from the gut to the brain through the vagus nerve. 
Despite growing supporting evidence for Braak’s hypothesis, factors promoting α-synuclein 
aggregation and the mechanism underlying PD neurodegeneration remain elusive. One 
proposed mechanism suggests that, through one path, GI inflammatory triggers exert 
deleterious effects on gut microbiota, intestinal permeability, and induce α-synuclein 
aggregation in the ENS, which later migrates to the CNS; and through another path, intestinal 
inflammation and altered permeability may promote systemic inflammation and subsequently 
increase the blood-brain barrier permeability 34. Together, the two paths may jointly lead to 
neuroinflammation and neurodegeneration34.  
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Limited epidemiological evidence exists on the possible prospective association of gut 
microbiota and intestinal inflammation with PD risk. Few studies have focused on Helicobacter 
pylori (HP) infection in relation to PD risk and results are somewhat controversial 128 129. A 
Danish register-based study reported an increased PD risk for treatment to HP infection but not 
for gastritis or peptic ulcers 128. A later study reported that HP infection, but not the treatment, 
was associated with a higher subsequent PD risk 129, in which the authors appeared to neglect 
the potential reverse causation between PD and HP infection 129. Indeed, HP infection130, small 
intestinal bacterial overgrowth131 and dysbiosis32 were more prevalent in PD. Intestinal 
inflammation and elevated levels of pro-inflammatory cytokines were also observed in PD 
patients and linked to the disease duration132. Overall, evidence from epidemiological studies 
suggests an involvement of bacterial infection and intestinal inflammation in PD, but the 
potential causal direction remains to be explored. A recent study reported that viral infection 
could induce the expression of α-synuclein in the gut among children who received intestinal 
transplants and showed a positive correlation between α-synuclein expression and degree of 
upper GI inflammation 133. Another intriguing study based on animal models of PD reported 
the role of the microbiome in promoting neuroinflammation and α-synuclein mediated motor 
deficits 134 supporting microbiota as a risk factor for PD. From an epidemiological point of 
view, one may focus on GI diseases characterized by microbiota alteration and chronic 
inflammation, such as IBS and IBD 34, 36, 135, to address the involvement of gut-brain-
microbiota axis in PD etiology. Previous results on IBD are inconsistent136-138, while evidence 
on IBS in relation to PD risk is rare 86.  
In Study III, we found an elevated risk of PD associated with IBS. Similar results were noted 
for IBS identified from the NPR and by the symptom-based algorithm. These associations 
cannot be entirely attributed to confounding by age, sex, life style factors, and surveillance bias. 
Although the potential underlying mechanisms are unknown, the results in line with the 
proposed mechanism that gut microbiota and inflammation might contribute to PD etiology. On 
the other hand, we cannot rule out the possibility that PD prodromal symptoms such as 
constipation might be misdiagnosed as IBS, and that residual confounding as an alternative 
explanation to the results.  
According to the dual-hit hypothesis, neurotropic pathogens may invade the brain through the 
nasal routes and α-synuclein pathology may spread from the olfactory bulb to the connected 
regions of the brain 17, 18. In line with this, in Study II we found that truncal vagotomy was 
related to a 40% but not an entire reduction of PD risk. Poor sense of smell is the most 
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prevalent non-motor prodromal symptom in PD 4 and is strongly linked to higher risk of PD in 
the general population 139. Olfactory dysfunction is also considered an early sign of 
neurodegeneration in general, which can precede clinical diagnosis of PD, AD, Lewy body 
dementia, and cognitive decline by many years 140. In Study IV, we found that the association 
between poor sense of smell and higher all-cause mortality was partly explained by 
PD/dementia and body weight loss. These results supports the pathway from poor olfaction, to 
neurodegeneration and related body weight loss, and ultimately to death. The study indicates 
the relevance of using olfaction test as a tool to detect early PD and revealed that 
neurodegeneration and body weight loss constitute part of the mechanisms underlying the 
association between poor olfaction and mortality.  
6.2 METHODOLOGICAL CONSIDERATIONS  
6.2.1 Bias 
Bias is defined as “systematic deviation of results or inference from the truth” 141 and exist in 
nearly all observational studies. Biases can arise due to, for example, systematic errors in study 
design (e.g. sampling bias, selection bias), data collection (e.g. information bias, recall bias), 
analysis (e.g. confounding, selection bias). As systematic errors may distort results towards 
both directions, the magnitude of the bias is usually not straightforward to quantify. Therefore, 
it is crucial to understand potential biases before interpreting results and drawing conclusions. 
Given the longitudinal design and use of register-based data, the four studies compiled in the 
thesis are insusceptible to recall bias. However, other types of bias may be present and deserve 
awareness and reflection.  
6.2.1.1 Measurement error and misclassification 
Measurement error may result in misclassifications. A misclassification that is independent of 
other variables is usually described as non-differential misclassification while its counterpart is 
called differential misclassification. Non-differential misclassification generally drives the 
association between exposure and outcome towards null, while differential misclassification 
can bias the results in both directions.  
In Study I, we obtained information on early life factors from the MGR and nationwide data on 
influenza-like-illness from the Swedish Public Health Agency. Coverage of these data are high 
making the concern of measurement error minor. However, the use of sibling structure, birth 
season and month, as surrogates of overall childhood infection certainly leads to some degree 
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of misclassifications. Ecologic analysis on the integrated influenza activity data also hinders the 
ability to assess the relationship between prenatal infection and PD risk. We however speculate 
that such misclassification of exposure is likely to be non-differential. Therefore, null 
associations of early life characteristics with PD cannot rule out a potential influence of 
prenatal and neonatal infections on later PD risk.  
In Study II, we ascertained vagotomy from the NPR. Although the validity of  the vagotomy 
procedure has not been evaluated, high accuracy of other surgeries in the GI, such as 
appendicitis has been reported 142. Moreover, classification of truncal and selective subtypes 
was made by an abdominal surgeon in our team after reviewing the surgical codes. 
Nevertheless, since coverage of the NPR increased over time and was not nationwide until 
1987, it is possible that some vagotomized patients may have been misclassified as vagotomy-
free individuals. Such under-diagnosis could also happen in PD identification during the earlier 
years of the NPR. Incomplete coverage may lead to a spurious positive relationship between 
vagotomy and PD, namely, vagotomy and PD diagnoses are likely to be captured 
coincidentally among people covered by the NPR. To minimize this bias, we generally 
restricted the study population to those living in counties covered by NPR in the 1970s. 
However, as we observed a lower risk of PD for vagotomy, bias due to incomplete coverage 
most likely would have driven the association towards null.   
It has been reported that only a proportion of IBS patients seek care and patients treated by 
specialists are more severe cases compared to those treated in primary care 143 144, 145. In Study 
III, IBS patients treated by specialists were captured by the NPR. Those who did not seek 
medical care or were treated in primary care might be identified by self-reported symptoms 
from the STR. However, under-diagnosis and misclassification of IBS are inevitable for both 
sources and may result in either an over- or under-estimation of the association. 
PD patients in Studies I-III were ascertained from the NPR. In a validation study of the NPR, 
the positive predictive value (PPV) of any inpatient PD diagnosis (primary or secondary) was 
70.8% compared to the gold-standard clinical work-up, and the PPV increased to 80.3% when 
restricted to primary inpatient diagnoses 146. In Studies I and III, when restricting the PD 
outcome to primary diagnoses only, the results remained similar. Although outpatient PD has 
not been validated, 92.5% of outpatient PD are primary diagnoses compared to 27% of 
inpatient diagnoses. Therefore, it is reasonable to assume that PD outpatient diagnoses are more 
accurate than inpatient ones.  
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In Study IV, olfaction was measured using the BSIT score. This test has been validated and is 
widely used in epidemiological studies 112, 113. Cut-offs for the BSIT score (≤8, 9-10, 11-12) 
were based on both the test norm 112 and their previous applications in epidemiological studies 
147 148. However, we were not able to differentiate causes of olfactory impairments either due to 
aging or other diseases. Moreover, olfactory function was only measured once, thus the 
trajectory in association with mortality was unknown. Nevertheless, measurement error on 
covariates and mortality is likely minor, since information on diseases and conditions collected 
in the Heath ABC study has been adjudicated by a consensus panel of physicians. 
6.2.1.2 Confounding  
Due to lack of information, analyses based on Swedish nationwide registers usually only 
consider a limited number of covariates. As we did not have information on potentially 
important confounders such as smoking, alcohol consumption, coffee drinking, medication use, 
and genetics, we attempted to address unmeasured confounding by using proxies, for example, 
COPD as a proxy for smoking. However, such analyses have been criticized because potential 
misclassification may be substantial. Indeed, life-long smokers may have a 50% probability of 
developing COPD 149 and 25–45% of COPD patients have never smoked 150. Although 
adjusting for proxies of unmeasured confounders is not optimal, it may still provide some 
useful indication on the direction of the confounding effect. New methods have been developed 
to quantify the robustness of the results to unmeasured confounding. For instance, one can 
calculate the E-value, a measure of the minimum strength of association that an unmeasured 
confounder would have with both exposure and outcome, in order to explain away the observed 
association 151. A large E-value implies that results are robust to a large unmeasured 
confounding effect 151.  
6.2.1.3 Selection bias 
Selection bias and sampling error is unlikely in Studies I-III which are based on the entire 
population of Sweden, but likely in Study IV, which is based on the Health ABC cohort 
comprising relatively healthy and well-functioning older adults. Selection bias may also arise 
from statistical analysis. In Study II, we evaluated the temporal relationship between vagotomy 
and PD risk and presented period-specific HR after 5, 10, and 20 years of follow-up. Since a 
period-specific HR is conditional on survival at the previous period of time, selection bias may 
be introduced if an unmeasured confounding has an impact on both previous survival and later 
outcome 152. The direction of such bias is however unknown. In contrast to HR, standardized 
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survival or failure curves are not susceptible to such shortcoming. The cumulative incidence 
plot in Study II demonstrated a lower PD risk after truncal vagotomy indicating potential 
selection bias was likely not an issue. In Studies III and IV, we presented the standardized 
survival curves in addition to the HRs. 
6.2.2 Assumptions for mediation analysis 
In Study IV, we performed mediation analysis to explore whether the association between 
olfaction and mortality can be explained by PD/dementia or weight loss. As mentioned in Fig 
4.2.2 we need four assumptions in order to estimate the direct and indirect effects: 1) no 
unmeasured exposure-outcome confounders given X0; 2) no unmeasured mediator-outcome 
confounders given W1 and W2; 3) no unmeasured exposure-mediator confounders given X1 and 
X2; 4) no mediator-outcome confounder W1 and W2 affected by A. 
Assumptions 1 and 3 are likely to hold because exposure-outcome and exposure-mediator 
confounders (X0, X1 and X2) are likely to be included in the wide range of baseline variables 
regarding demographic, behavior and life-style, and comorbidities. Further, assumption 2 may 
also be fulfilled. We attempted to incorporate most of the suggested confounders for the 
association between PD/dementia and mortality (such as age, sex, race, life-style factors and 
baseline comorbidities) in W1 
153, 154.  Important confounders for the association between body 
weight loss and mortality155, such as age, sex, race, baseline BMI, smoking and alcohol 
consumption, and metabolic diseases have been considered in W2. We also assume that no 
mediator-outcome confounder is affected by exposure (assumption 4). However, violation of 
this assumption is difficult to assess.  
6.3 ETHICAL CONSIDERATIONS 
Studies I-III are register-based studies and have been approved by the Regional Ethics 
Committee in Stockholm. Informed consent is not required for the use of register data. 
Researchers who work with these data are obligated to take care to de-identify individuals as to 
protect the anonymity of the person. The National Board of Health and Welfare has replaced 
the personal identity number with a serial number, meaning that all individuals in the register 
are anonymized. Furthermore, register data are secured by Karolinska Institutet through strict 
safety control and regulations of data access. In Study IV, the study protocol was approved by 
all relevant Institutional Review Boards (IRB). All study participants provided informed 
consent at enrollment and all the analyses were based on de-identified data. 
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6.4 CONCLUSION 
Taken together, this thesis provides several important findings: 1) we found little evidence 
supporting the development origin of PD, while the influence of specific intrauterine, pre- and 
neonatal infections remains to be elucidated and clarified; 2) lower PD risk associated with 
truncal vagotomy and elevated PD risk related to IBS highlight the importance of the gut-brain 
axis in the etiology of PD. Further studies on the potential mechanisms involving for instance 
intestinal inflammation and disturbance of gut microbiota are warranted; 3) we confirmed the 
association between poor olfaction and mortality and identified important mechanisms for this 
association through neurodegenerative disease such as PD and dementia as well as weight loss. 
6.5 FUTURE PROSPECTIVES 
Although the causes and underlying mechanism of PD remain unclear, special attention has 
been paid to Braak’s hypothesis and the gut-brain connection. Further efforts are warranted to 
explore physiological conditions and factors that may affect the misfolding and aggregation of 
α-synuclein. Future research should be encouraged to elucidate the influence of viral and 
bacterial infections and related immune responses in the development PD. Differential 
abundances of gut microbes were observed in PD 31-33, and also in patients with RBD 156 that is 
a strong predictor of PD 157. Prospective studies with reliable and repetitive measurements are 
essential to capture changes in the composition of microbiota in relation to PD risk. Moreover, 
human herpesviruses was recently linked to the etiology of AD 158, while the potential influence 
of viral infection on PD remains to be explored.  
Studies on potential therapeutic roles of antibiotics, probiotics, anti-inflammatory drugs are also 
highly warranted. Lower PD risk has been linked to use of ibuprofen, but not other NSAIDs 63. 
Intriguing results were reported very recently demonstrating the protective effect of anti-
asthmatic drugs (i.e. beta2-adrenoreceptor stimulators)159 and TNF-α inhibitors 138 on PD risk. 
Understanding the specific functions of pro-inflammatory molecules and the distribution of 
corresponding receptors may give us new perspectives in searching candidate targets for 
pharmaceutical treatments. Given the potential involvement of gut-brain-microbiota axis in PD 
etiology, future research are encouraged to explore the potential impact of antibiotics and 
probiotics on the etiology and development of PD. 
Early detection of PD is particularly important given that once motor symptoms present, the 
majority of the dopaminergic neurons are already lost. Olfactory loss was included in the MDS 
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diagnostic criteria of prodromal PD 160 and results from Study IV also suggests the importance 
of olfaction tests. A recent study demonstrated that patterns of olfactory impairment may vary 
by different etiologies and that PD patients had poor performance in odor identification and 
discrimination but better performance on the odor threshold task 161. Continued efforts are 
needed to optimize relevant tests and establish reliable biomarkers and criteria for early PD 
identification in population settings. 
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